Oryzon Genomics SA (ORYZF)
3.645
-0.06
(-1.49%)
USD |
OTCM |
Jun 10, 16:00
Oryzon Genomics Total Assets (Quarterly) : 163.27M for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 163.27M |
| December 31, 2025 | 169.74M |
| September 30, 2025 | 171.17M |
| June 30, 2025 | 162.40M |
| March 31, 2025 | 115.93M |
| December 31, 2024 | 113.75M |
| September 30, 2024 | 122.27M |
| June 30, 2024 | 118.61M |
| March 31, 2024 | 116.29M |
| December 31, 2023 | 118.09M |
| September 30, 2023 | 108.24M |
| June 30, 2023 | 114.16M |
| March 31, 2023 | 112.21M |
| December 31, 2022 | 110.67M |
| September 30, 2022 | 103.67M |
| June 30, 2022 | 100.71M |
| March 31, 2022 | 103.70M |
| December 31, 2021 | |
| September 30, 2021 | 109.19M |
| June 30, 2021 | 112.99M |
| March 31, 2021 | 112.14M |
| Date | Value |
|---|---|
| December 31, 2020 | 115.14M |
| September 30, 2020 | 113.40M |
| June 30, 2020 | 112.46M |
| March 31, 2020 | 84.60M |
| December 31, 2019 | 89.91M |
| September 30, 2019 | 87.70M |
| June 30, 2019 | 73.18M |
| March 31, 2019 | 73.12M |
| December 31, 2018 | 77.11M |
| September 30, 2018 | 65.37M |
| June 30, 2018 | 68.46M |
| March 31, 2018 | 72.59M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 56.67M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Pharma Mar SA | 443.90M |
| Grifols SA | 23.13B |
| ACADIA Pharmaceuticals, Inc. | 1.605B |
| Alkermes Plc | 4.258B |
| Alnylam Pharmaceuticals, Inc. | 5.130B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 26.97M |
| Shareholders Equity (Quarterly) | 120.20M |
| Debt to Equity Ratio | 0.0681 |
| Current Ratio | 1.834 |
| Net Debt Paydown Yield | 0.66% |